Described herein are hepatitis B capsid assembly modulator compounds of formula (I) and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

##STR00001##

Described herein are hepatitis B capsid assembly modulator compounds of formula (I) and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

##STR00001##

Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

The present invention relates to a process for purification of protected polycyclic carbamoylpyridone derivatives and its conversion to polycyclic carbamoylpyridone derivatives or its pharmaceutically acceptable salts thereof.

The present invention relates to a process for purification of protected polycyclic carbamoylpyridone derivatives and its conversion to polycyclic carbamoylpyridone derivatives or its pharmaceutically acceptable salts thereof.

Provided herein are Heteroaryl Compounds having the following structure:

##STR00001##

wherein R.sup.1-R.sup.4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

Provided herein are Heteroaryl Compounds having the following structure:

##STR00001##

wherein R.sup.1-R.sup.4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound.

An arenavirus proliferation inhibitor comprising a compound represented by Formula (I) or a prodrug thereof or a pharmaceutically acceptable salt thereof.

##STR00001##

(wherein R.sup.1 is carboxy, or the like: A.sup.3 is CR.sup.2 or N; R.sup.2 is a hydrogen atom, halogen, hydroxy, or the like: R.sup.3 is a hydrogen atom, hydroxy, carboxy, cyano, formyl, alkyl optionally substituted with Substituent group F, or the like; either A.sup.1 or A.sup.2 is CR.sup.5R.sup.6, and the other is NR.sup.7, or A.sup.1 is CR.sup.8R.sup.9, and A.sup.2 is CR.sup.10OR.sup.11; and R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, and R.sup.11 are each independently a hydrogen atom, carboxy, cyano, alkyl optionally substituted with Substituent group F, or the like).

The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound.

An arenavirus proliferation inhibitor comprising a compound represented by Formula (I) or a prodrug thereof or a pharmaceutically acceptable salt thereof.

##STR00001##

(wherein R.sup.1 is carboxy, or the like: A.sup.3 is CR.sup.2 or N; R.sup.2 is a hydrogen atom, halogen, hydroxy, or the like: R.sup.3 is a hydrogen atom, hydroxy, carboxy, cyano, formyl, alkyl optionally substituted with Substituent group F, or the like; either A.sup.1 or A.sup.2 is CR.sup.5R.sup.6, and the other is NR.sup.7, or A.sup.1 is CR.sup.8R.sup.9, and A.sup.2 is CR.sup.10OR.sup.11; and R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, and R.sup.11 are each independently a hydrogen atom, carboxy, cyano, alkyl optionally substituted with Substituent group F, or the like).